Therapies targeting interleukins such as IL-6 (e.g., tocilizumab) and IL-5 (e.g., mepolizumab) have been explored, particularly in eosinophilic granulomatosis with polyangiitis (EGPA), a subset of AAV. The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.